at the site.

Our focus is a new solution
for chronic rhinosinusitis.

Lyra Therapeutics is
at the point
of impact for CRS

Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS).

Changing the status quo for crs

Chronic rhinosinusitis (CRS) is a debilitating inflammatory disease that causes months or years of nasal congestion, facial pain and pressure, and nasal discharge for 14 million people in the United States, yet many lack effective, long-lasting treatment options. At Lyra Therapeutics, we are developing a new solution for CRS.

CRS-tailored Solutions

We aim to break the relentless medical management cycle for this underserved population by bringing a new treatment option for CRS.

Long-Acting Drug Therapy

Our CRS product candidates are designed to provide long-acting medication directly to sinonasal tissues that are not accessible with conventional therapeutic approaches.

High-impact Team

We’re a team of experienced drug developers who are passionate about changing the way we treat CRS.

How Lyra Therapeutics treats CRS
at the site

How LYR-210 Works

Lyra Therapeutics’ lead product candidate, LYR-210, is a bioabsorbable nasal mesh designed to deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages for the treatment of CRS.

Lyra Therapeutics
Lyra Therapeutics
Lyra Therapeutics
Lyra Therapeutics
Lyra Therapeutics

A new solution
for an under-recognized

CRS is very common, yet it is often downplayed or misunderstood. CRS patients struggle with painful, persistent symptoms and cycle through treatment options to try to find lasting relief. Hear from the real heroes of CRS – the people who are doing their best to manage the disease every day.


of Materials Science
and Drug Development

Our proprietary technology integrates a proven anti-inflammatory medication and advanced materials engineering to create a treatment solution for CRS. Lyra Therapeutics’ drug-eluting nasal mesh adapts to the sinonasal passages where CRS treatment is needed, enabling sustained delivery of medication in a single administration.

Lyra Therapeutics
Lyra Therapeutics

Join us
at the point
of possibilities.

Lyra Therapeutics is at a pivotal point of development, with product candidates on the path toward commercialization. Our possibilities come from our people, as we create our future together.

Back to Top